Saturday 17 October 2026
Export FBLG’s income statement to Excel — free account
FibroBiologics Inc.
FBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.5% and free cash flow grew 21.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.95
0.05
−5.00%
Follow FBLG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (660.08%) | (754.75%) | (419.44%) | (1,292.87%) |
+8 more TTM periods Free account |
|
| (166.14%) | (215.16%) | (143.08%) | (192.59%) | ||
ROIC |
(932.71%) | (960.76%) | (824.53%) | 0.00% | |
Return on Tangible Assets |
(417.28%) | (1,008.64%) | (343.26%) | 3,223.17% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.36) | (4.10) | (7.46) | (7.74) | |
Free Cash Flow |
(14.79) | (15.48) | (16.66) | (16.66) | |
Capital Expenditures |
— | — | (0.26) | (0.36) | |
| Other line items | |||||
Cash ROIC |
(181.45%) | (379.30%) | (150.73%) | (174.23%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(760.41) | (859.30) | — | — | |
Operating CF/Net income |
0.82 | 0.83 | 0.88 | 0.88 | |
Depreciation/Fixed assets |
1.22 | 1.17 | 0.99 | 0.83 | |
Capex/Depreciation |
0.00 | 0.00 | (0.31) | (0.48) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.36) | (4.10) | (7.34) | (7.57) | |
Capex per Share |
0.00 | 0.00 | (0.12) | (0.17) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates